Ovarian cancer

The Lancet

Volumn 384, Issue 9951, 2014, Pages 1376-1388

  Jayson, Gordon C ^a   Kohn, Elise C ^b   Kitchener, Henry C ^a   Ledermann, Jonathan A ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; GLYCOSYLTRANSFERASE INHIBITOR; PLATINUM; ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADVANCED CANCER; ANTIANGIOGENIC THERAPY; BONE DENSITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOSENSITIVITY; CLEAR CELL CARCINOMA; CYTOTOXICITY; DISEASE FREE INTERVAL; DRUG EFFICACY; EARLY DIAGNOSIS; ENDOMETRIOID CARCINOMA; FEMALE; GENE DELETION; GENETIC DISORDER; GENOMIC INSTABILITY; GERMLINE MUTATION; HISTOPATHOLOGY; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE OBSTRUCTION; MOLECULAR PATHOLOGY; MULTIMODALITY CANCER THERAPY; OVARY CARCINOMA; POSTMENOPAUSE; REVIEW; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; FORECASTING; GENETICS; METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROCEDURES; PROGNOSIS; TUMOR SUPPRESSOR GENE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; EARLY DETECTION OF CANCER; FEMALE; FORECASTING; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS;

EID: 84908173579     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62146-7     Document Type: Review

References (131)

1. International Agency for Research on Cancer Global cancer statistics http://globocan.iarc.fr/Pages/fact-sheets-population.aspx 2008 (accessed Feb 17, 2014).
2. D Jelovac, DK Armstrong Recent progress in the diagnosis and treatment of ovarian cancer CA Cancer J Clin 61 2011 183 203
3. UK Cancer Research Ovarian cancer incidence statistics http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/incidence/uk-ovarian-cancer-incidence-statistics 2013 (accessed March 24, 2014).
4. A Jemal, F Bray, MM Center, J Ferlay, E Ward, D Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
5. I Soerjomataram, J Lortet-Tieulent, DM Parkin et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions Lancet 380 2012 1840 1850
6. N Mavaddat, S Peock, D Frost the EMBRACE Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE J Natl Cancer Inst 105 2013 812 822
7. KK Tsilidis, NE Allen, TJ Key et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition Br J Cancer 105 2011 1436 1442
8. W Sieh, S Salvador, V McGuire the Australian Cancer Study (Ovarian Cancer) the Australian Ovarian Cancer Study Group the Ovarian Cancer Association Consortium Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies Int J Epidemiol 42 2013 579 589
9. LM Stewart, CD Holman, JC Finn, DB Preen, R Hart In vitro fertilization is associated with an increased risk of borderline ovarian tumours Gynecol Oncol 129 2013 372 376
10. PS Munksgaard, J Blaakaer The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations Gynecol Oncol 124 2012 164 169
11. KC Wiegand, SP Shah, OM Al-Agha et al. ARID1A mutations in endometriosis-associated ovarian carcinomas N Engl J Med 363 2010 1532 1543
12. BG Chittenden, G Fullerton, A Maheshwari, S Bhattacharya Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review Reprod Biomed Online 19 2009 398 405
13. CL Pearce, C Templeman, MA Rossing for the Ovarian Cancer Association Consortium Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies Lancet Oncol 13 2012 385 394
14. M Anttila, S Syrjänen, H Ji, S Saarikoski, K Syrjänen Failure to demonstrate human papillomavirus DNA in epithelial ovarian cancer by general primer PCR Gynecol Oncol 72 1999 337 341
15. DM Gertig, DJ Hunter, DW Cramer et al. Prospective study of talc use and ovarian cancer J Natl Cancer Inst 92 2000 249 252
16. V Beral, K Gaitskell, C Hermon for the Collaborative Group on Epidemiological Studies of Ovarian Cancer Ovarian cancer and smoking: individual participant meta-analysis including 28 114 women with ovarian cancer from 51 epidemiological studies Lancet Oncol 13 2012 946 956
17. A Antoniou, PDP Pharoah, S Narod et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies Am J Hum Genet 72 2003 1117 1130
18. FJ Couch, X Wang, L McGuffog the kConFab Investigators the SWE-BRCA the Ontario Cancer Genetics Network the HEBON the EMBRACE the GEMO Study Collaborators the BCFR the CIMBA Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk PLoS Genet 9 2013 e1003212
19. T Pal, MR Akbari, P Sun et al. Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer Br J Cancer 107 2012 1783 1790
20. S Simchoni, E Friedman, B Kaufman et al. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population Proc Natl Acad Sci USA 103 2006 3770 3774
21. AK Folkins, TA Longacre Hereditary gynaecological malignancies: advances in screening and treatment Histopathology 62 2013 2 30
22. M Köbel, SE Kalloger, N Boyd et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies PLoS Med 5 2008 e232
23. A Ayhan, RJ Kurman, A Yemelyanova et al. Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis Am J Surg Pathol 33 2009 1220 1224
24. CG Hannibal, R Vang, J Junge, A Kjaerbye-Thygesen, RJ Kurman, SK Kjaer A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006 Gynecol Oncol 125 2012 655 660
25. S Banerjee, SB Kaye New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential Clin Cancer Res 19 2013 961 968
26. IM Shih, RJ Kurman Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis Am J Pathol 164 2004 1511 1518
27. D Bell, A Berchuck, M Birrer the Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
28. M Köbel, A Reuss, A Bois et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas J Pathol 222 2010 191 198
29. AA Ahmed, D Etemadmoghadam, J Temple et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary J Pathol 221 2010 49 56
30. DW Kindelberger, Y Lee, A Miron et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship Am J Surg Pathol 31 2007 161 169
31. F Medeiros, MG Muto, Y Lee et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome Am J Surg Pathol 30 2006 230 236
32. RW Tothill, AV Tinker, J George the Australian Ovarian Cancer Study Group Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome Clin Cancer Res 14 2008 5198 5208
33. J Farley, WE Brady, V Vathipadiekal et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study Lancet Oncol 14 2013 134 140
34. MS Anglesio, J George, H Kulbe the Australian Ovarian Cancer Study Group IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer Clin Cancer Res 17 2011 2538 2548
35. BA Goff, LS Mandel, CH Melancon, HG Muntz Frequency of symptoms of ovarian cancer in women presenting to primary care clinics JAMA 291 2004 2705 2712
36. CR Bankhead, C Collins, H Stokes-Lampard et al. Identifying symptoms of ovarian cancer: a qualitative and quantitative study BJOG 115 2008 1008 1014
37. National Institute for Health and Care Excellence (NICE) Ovarian cancer: the recognition and initial management of ovarian cancer http://www.nice.org.uk/guidance/CG122 2011 (accessed Dec 17, 2013).
38. M-C King, JH Marks, JB Mandell, TNYBCS Group for the New York Breast Cancer Study Group Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 Science 302 2003 643 646
39. ND Kauff, JM Satagopan, ME Robson et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation N Engl J Med 346 2002 1609 1615
40. I Jacobs, D Oram, J Fairbanks, J Turner, C Frost, JG Grudzinskas A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer Br J Obstet Gynaecol 97 1990 922 929
41. J Prat for the FIGO Committee on Gynecologic Oncology Staging classification for cancer of the ovary, fallopian tube, and peritoneum Int J Gynaecol Obstet 124 2014 1 5
42. MEL van der Burg, M van Lent, M Buyse for the Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer N Engl J Med 332 1995 629 634
43. PG Rose, S Nerenstone, MF Brady the Gynecologic Oncology Group Secondary surgical cytoreduction for advanced ovarian carcinoma N Engl J Med 351 2004 2489 2497
44. EJ Junor, DJ Hole, L McNulty, M Mason, J Young Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients Br J Obstet Gynaecol 106 1999 1130 1136
45. PB Panici, A Maggioni, N Hacker et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial J Natl Cancer Inst 97 2005 560 566
46. CA Powless, GD Aletti, JN Bakkum-Gamez, WA Cliby Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging Gynecol Oncol 122 2011 536 540
47. GD Aletti, BS Gostout, KC Podratz, WA Cliby Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon Gynecol Oncol 100 2006 33 37
48. A du Bois, A Reuss, E Pujade-Lauraine, P Harter, I Ray-Coquard, J Pfisterer Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer 115 2009 1234 1244
49. JB Trimbos, M Parmar, I Vergote the International Collaborative Ovarian Neoplasm 1 the European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma J Natl Cancer Inst 95 2003 105 112
50. JB Trimbos, I Vergote, G Bolis the EORTC-ACTION collaborators European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial J Natl Cancer Inst 95 2003 113 125
51. S Kehoe Second look laparotomy and ovarian cancer J Surg Oncol 57 1994 205
52. B Trimbos, P Timmers, S Pecorelli et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial J Natl Cancer Inst 102 2010 982 987
53. Swart AC, for ICON collaborators. Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON1). American Society of Clinical Oncology (ASCO) 43rd Annual Meeting; Chicago, IL; June 1-5. 5509.
54. DK Armstrong, B Bundy, L Wenzel the Gynecologic Oncology Group Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43
55. N Katsumata, M Yasuda, F Takahashi the Japanese Gynecologic Oncology Group Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial Lancet 374 2009 1331 1338
56. RA Burger, MF Brady, MA Bookman the Gynecologic Oncology Group Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2011 2473 2483
57. TJ Perren, AM Swart, J Pfisterer the ICON7 Investigators A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 2011 2484 2496
58. C Aghajanian, SV Blank, BA Goff et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 30 2012 2039 2045
59. Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). 2012 Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; June 1-5, 2012. LBA5002.
60. J Ledermann, P Harter, C Gourley et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer N Engl J Med 366 2012 1382 1392
61. WP McGuire, WJ Hoskins, MF Brady et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6
62. RF Ozols, BN Bundy, BE Greer the Gynecologic Oncology Group Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200
63. PA Vasey, GC Jayson, A Gordon the Scottish Gynaecological Cancer Trials Group Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma J Natl Cancer Inst 96 2004 1682 1691
64. MA Bookman, MF Brady, WP McGuire et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup J Clin Oncol 27 2009 1419 1425
65. TJ Herzog, JB Vermorken, E Pujade-Lauraine et al. Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study Gynecol Oncol 122 2011 350 355
66. GJ Rustin, AE Nelstrop, P McClean et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 J Clin Oncol 14 1996 1545 1551
67. GJS Rustin, P Timmers, A Nelstrop et al. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide J Clin Oncol 24 2006 45 51
68. A du Bois, A Floquet, K Jae Weon et al. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16). 2013 Annual Meeting of the American Society of Clinical Oncology; Chicaga; May 31 - June 4, 2013 J Clin Oncol 31 2013 LBA5503
69. N Katsumata, M Yasuda, S Isonishi the Japanese Gynecologic Oncology Group Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial Lancet Oncol 14 2013 1020 1026
70. GCIG GCIG criteria for Ca125 in ovarian cancer http://www.gcig.igcs.org/CA-125.html (accessed Feb 10, 2014).
71. P Harter, J Sehouli, A Reuss et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO Int J Gynecol Cancer 21 2011 289 295
72. GJ Rustin, ME van der Burg, CL Griffin the MRC OV05 the EORTC 55955 investigators Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial Lancet 376 2010 1155 1163
73. M Markman, R Rothman, T Hakes et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J Clin Oncol 9 1991 389 393
74. EA Eisenhauer, JB Vermorken, M van Glabbeke Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients Ann Oncol 8 1997 963 968
75. M Markman, R Rothman, T Hakes et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J Clin Oncol 9 1991 389 393
76. MK Parmar, JA Ledermann, N Colombo the ICON and AGO Collaborators Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 2003 2099 2106
77. AJ González-Martín, E Calvo, I Bover et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study Ann Oncol 16 2005 749 755
78. J Pfisterer, M Plante, I Vergote the AGO-OVAR the NCIC CTG the EORTC GCG Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J Clin Oncol 24 2006 4699 4707
79. E Pujade-Lauraine, U Wagner, E Aavall-Lundqvist et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse J Clin Oncol 28 2010 3323 3329
80. AN Gordon, JT Fleagle, D Guthrie, DE Parkin, ME Gore, AJ Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 2001 3312 3322
81. T Meyer, AE Nelstrop, M Mahmoudi, GJS Rustin Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer Ann Oncol 12 2001 1705 1709
82. R Sharma, J Graham, H Mitchell, A Brooks, S Blagden, H Gabra Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer Br J Cancer 100 2009 707 712
83. ME van der Burg, R de Wit, WL van Putten et al. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer Br J Cancer 86 2002 19 25
84. IA Cree, CM Kurbacher, A Lamont, AC Hindley, S Love the TCA Ovarian Cancer Trial Group A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer Anticancer Drugs 18 2007 1093 1101
85. HJ Burstein, PB Mangu, MR Somerfield the American Society of Clinical Oncology American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays J Clin Oncol 29 2011 3328 3330
86. JZ Press, A De Luca, N Boyd et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities BMC Cancer 8 2008 17
87. KL Bolton, G Chenevix-Trench, C Goh the EMBRACE the kConFab Investigators the Cancer Genome Atlas Research Network Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer JAMA 307 2012 382 390
88. K Alsop, S Fereday, C Meldrum et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group J Clin Oncol 30 2012 2654 2663
89. C Gourley, CO Michie, P Roxburgh et al. Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2010 2505 2511
90. PC Fong, DS Boss, TA Yap et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2009 123 134
91. SB Kaye, J Lubinski, U Matulonis et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer J Clin Oncol 30 2012 372 379
92. J Ledermann, P Harter, C Gourley et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm) J Clin Oncol 31 2013 5505
93. WH Gotlieb, F Amant, S Advani et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study Lancet Oncol 13 2012 154 162
94. Ledermann JA, Perren TJ, Raja FA, et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. European Cancer Congress 2013; Amsterdam; Sept 27-Oct 1, 2013.
95. V Möbus, H Wandt, N Frickhofen the AGO-Ovar/AIO the EBMT Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT J Clin Oncol 25 2007 4187 4193
96. S De Placido, G Scambia, G Di Vagno et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study J Clin Oncol 22 2004 2635 2642
97. S Pecorelli, G Favalli, A Gadducci for the After 6 Italian Cooperative Group Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1 J Clin Oncol 27 2009 4642 4648
98. MR Mancuso, R Davis, SM Norberg et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition J Clin Invest 116 2006 2610 2621
99. D Stark, M Nankivell, E Pujade-Lauraine et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial Lancet Oncol 14 2013 236 243
100. BJ Monk, HQ Huang, RA Burger et al. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study Gynecol Oncol 128 2013 573 578
101. SA Cannistra, UA Matulonis, RT Penson et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 2007 5180 5186
102. BY Karlan, AM Oza, GE Richardson et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer J Clin Oncol 30 2012 362 371
103. J Berek, P Taylor, W McGuire, LM Smith, B Schultes, CF Nicodemus Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer J Clin Oncol 27 2009 418 425
104. JA Konner, KM Bell-McGuinn, P Sabbatini et al. Farletuzumab, a humanized monoclonal antibody against folate receptor α, in epithelial ovarian cancer: a phase I study Clin Cancer Res 16 2010 5288 5295
105. PM Lorusso, MJ Edelman, SL Bever et al. Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors J Clin Oncol 30 2012 4011 4016
106. R Naumann, R Coleman, R Burger et al. PRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer J Clin Oncol 29 suppl 15 2011 5045
107. DA Altomare, HQ Wang, KL Skele et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth Oncogene 23 2004 5853 5857
108. K Behbakht, MW Sill, KM Darcy et al. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study Gynecol Oncol 123 2011 19 26
109. KWL Yee, Z Zeng, M Konopleva et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies Clin Cancer Res 12 2006 5165 5173
110. DS Hong, DW Bowles, GS Falchook et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors Clin Cancer Res 18 2012 4173 4182
111. B Markman, J Tabernero, I Krop et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors Ann Oncol 23 2012 2399 2408
112. JA Ledermann, A Hackshaw, S Kaye et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer J Clin Oncol 29 2011 3798 3804
113. E Gherardi, W Birchmeier, C Birchmeier, G Vande Woude Targeting MET in cancer: rationale and progress Nat Rev Cancer 12 2012 89 103
114. JD Ahlgren, NM Ellison, RJ Gottlieb et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program J Clin Oncol 11 1993 1957 1968
115. A Bowman, H Gabra, SP Langdon et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup Clin Cancer Res 8 2002 2233 2239
116. JF Smyth, C Gourley, G Walker et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients Clin Cancer Res 13 2007 3617 3622
117. DM Gershenson, CC Sun, D Bodurka et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant Gynecol Oncol 114 2009 48 52
118. RA Eeles, S Tan, E Wiltshaw et al. Hormone replacement therapy and survival after surgery for ovarian cancer BMJ 302 1991 259 262
119. F Guidozzi, A Daponte Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial Cancer 86 1999 1013 1018
120. RL Stone, AM Nick, IA McNeish et al. Paraneoplastic thrombocytosis in ovarian cancer N Engl J Med 366 2012 610 618
121. UK Cancer Research Cancer survival rates: trends http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/survival/#Trends 2013 (accessed Feb 17, 2014).
122. UK Cancer Research Ovarian cancer survival statistics http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/survival/ovarian-cancer-survival-statistics 2013 (accessed Feb 10, 2014).
123. G Bolis, A Villa, P Guarnerio et al. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy Cancer 77 1996 128 131
124. RW Griffiths, YK Zee, S Evans et al. Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube Int J Gynecol Cancer 21 2011 58 65
125. MK Whitworth, A Whitfield, S Holm, J Shaffer, W Makin, GC Jayson Doctor, does this mean I'm going to starve to death? J Clin Oncol 22 2004 199 201
126. IJ Jacobs, SJ Skates, N MacDonald et al. Screening for ovarian cancer: a pilot randomised controlled trial Lancet 353 1999 1207 1210
127. SS Buys, E Partridge, A Black the PLCO Project Team Effect of screening on ovarian cancer mortality: The prostate, lung, colorectal and ovarian (plco) cancer screening randomized controlled trial JAMA 305 2011 2295 2303
128. U Menon, A Gentry-Maharaj, R Hallett et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) Lancet Oncol 10 2009 327 340
129. PDP Pharoah, Y-Y Tsai, SJ Ramus the Australian Cancer Study the Australian Ovarian Cancer Study Group GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer Nat Genet 45 2013 362 370 e1-2.
130. SE Bojesen, KA Pooley, SE Johnatty et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer Nat Genet 45 2013 371 384 e1-2.
131. AN Rosenthal, L Fraser, R Manchanda et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule J Clin Oncol 31 2013 49 57